Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
18F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib.
Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Kasuya K, Sano T, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H. Kawamura Y, et al. Among authors: shindoh j. Liver Cancer. 2020 Jan;9(1):84-92. doi: 10.1159/000503577. Epub 2019 Nov 13. Liver Cancer. 2020. PMID: 32071912 Free PMC article.
Microvascular Invasion and a Size Cutoff Value of 2 cm Predict Long-Term Oncological Outcome in Multiple Hepatocellular Carcinoma: Reappraisal of the American Joint Committee on Cancer Staging System and Validation Using the Surveillance, Epidemiology, and End-Results Database.
Shindoh J, Kobayashi Y, Kawamura Y, Akuta N, Kobayashi M, Suzuki Y, Ikeda K, Hashimoto M. Shindoh J, et al. Liver Cancer. 2020 Apr;9(2):156-166. doi: 10.1159/000504193. Epub 2019 Dec 11. Liver Cancer. 2020. PMID: 32399430 Free PMC article.
Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis.
Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Kasuya K, Sano T, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H. Kawamura Y, et al. Among authors: shindoh j. Liver Cancer. 2020 Jun;9(3):275-292. doi: 10.1159/000505190. Epub 2020 Feb 4. Liver Cancer. 2020. PMID: 32647631 Free PMC article.
Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma.
Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Tominaga L, Kajiwara A, Kasuya K, Iritani S, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kozuka T, Kumada H. Kawamura Y, et al. Among authors: shindoh j. Liver Cancer. 2020 Dec;9(6):756-770. doi: 10.1159/000510299. Epub 2020 Oct 30. Liver Cancer. 2020. PMID: 33442544 Free PMC article.
A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC Trial).
Ichida A, Arita J, Hatano E, Eguchi S, Saiura A, Nagano H, Shindoh J, Hashimoto M, Takemura N, Taura K, Sakamoto Y, Takahashi Y, Seyama Y, Sasaki Y, Uemura K, Kokudo N, Hasegawa K. Ichida A, et al. Among authors: shindoh j. Liver Cancer. 2023 Nov 28;13(3):322-334. doi: 10.1159/000535514. eCollection 2024 Jun. Liver Cancer. 2023. PMID: 38894811 Free PMC article.
Oncological Resectability Criteria for Hepatocellular Carcinoma in the Era of Novel Systemic Therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Expert Consensus Statement 2023.
Akahoshi K, Shindoh J, Tanabe M, Ariizumi S, Eguchi S, Okamura Y, Kaibori M, Kubo S, Shimada M, Taketomi A, Takemura N, Nagano H, Nakamura M, Hasegawa K, Hatano E, Yoshizumi T, Endo I, Kokudo N. Akahoshi K, et al. Among authors: shindoh j. Liver Cancer. 2024 Mar 29;13(6):0-10. doi: 10.1159/000538627. eCollection 2024 Dec. Liver Cancer. 2024. PMID: 39524972 Free PMC article.
225 results